Overview
BiotechPhase 3psilocybinDMT
Formerly Cybin Inc., rebranded to Helus Pharma in January 2026. Developing CYB003 (deuterated psilocybin) for major depressive disorder in Phase 3 trials, and CYB004 for generalized anxiety disorder.
Visit WebsiteToronto, Canada
6
Clinical Trials
2019
Founded
70
Employees
0
Open Roles
Open Positions
No open positions at this time
Research Areas
Clinical Pipeline(6)
Withdrawn·Phase 2·psilocybin
Effect of SSRIs on Response to Psilocybin Therapy
PsilocybinDepression
Recruiting·Phase 3·psilocybin
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
CYB003Major Depressive Disorder (MDD)
Enrolling by Invitation·Phase 3·psilocybin
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
CYB003Major Depressive Disorder
Recruiting·Phase 3·psilocybin
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
CYB003Major Depressive Disorder
Active, Not Recruiting·Phase 2·DMT
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
CYB004Generalized Anxiety Disorder
Completed·Phase 1·psilocybin
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
CYB003Major Depressive Disorder